Foamix Pharmaceuticals (FOMX) Reaches New 12-Month Low at $4.16

Share on StockTwits

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) shares reached a new 52-week low on Monday . The company traded as low as $4.16 and last traded at $4.20, with a volume of 7653 shares changing hands. The stock had previously closed at $4.29.

A number of research analysts recently weighed in on FOMX shares. HC Wainwright set a $11.00 price target on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 18th. Cantor Fitzgerald initiated coverage on shares of Foamix Pharmaceuticals in a research report on Thursday, October 11th. They issued an “overweight” rating on the stock. Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research report on Wednesday, September 19th. ValuEngine lowered shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Finally, BidaskClub lowered shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.25.

The stock has a market capitalization of $225.22 million, a P/E ratio of -2.36 and a beta of 2.10.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.10. The business had revenue of $0.96 million for the quarter, compared to analyst estimates of $1.10 million. Foamix Pharmaceuticals had a negative net margin of 2,085.71% and a negative return on equity of 131.84%. On average, analysts forecast that Foamix Pharmaceuticals Ltd will post -1.64 EPS for the current year.

In other Foamix Pharmaceuticals news, CEO David Domzalski sold 8,238 shares of Foamix Pharmaceuticals stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $5.68, for a total value of $46,791.84. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders sold 11,763 shares of company stock worth $66,910. Insiders own 3.30% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of FOMX. A.R.T. Advisors LLC bought a new stake in shares of Foamix Pharmaceuticals in the first quarter valued at approximately $104,000. Senzar Asset Management LLC bought a new stake in shares of Foamix Pharmaceuticals in the second quarter valued at approximately $338,000. ARK Investment Management LLC raised its position in shares of Foamix Pharmaceuticals by 17.7% in the second quarter. ARK Investment Management LLC now owns 106,243 shares of the specialty pharmaceutical company’s stock valued at $532,000 after purchasing an additional 15,980 shares during the period. Wells Fargo & Company MN raised its position in shares of Foamix Pharmaceuticals by 31.7% in the third quarter. Wells Fargo & Company MN now owns 132,900 shares of the specialty pharmaceutical company’s stock valued at $761,000 after purchasing an additional 32,013 shares during the period. Finally, Handelsbanken Fonder AB raised its position in shares of Foamix Pharmaceuticals by 7.0% in the second quarter. Handelsbanken Fonder AB now owns 390,000 shares of the specialty pharmaceutical company’s stock valued at $1,954,000 after purchasing an additional 25,500 shares during the period. 47.01% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Macon Daily and is the sole property of of Macon Daily. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://macondaily.com/2018/11/05/foamix-pharmaceuticals-fomx-reaches-new-12-month-low-at-4-16.html.

Foamix Pharmaceuticals Company Profile (NASDAQ:FOMX)

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

Further Reading: Technical Analysis

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply